TR 14035

Drug Profile

TR 14035

Alternative Names: SB 683698

Latest Information Update: 24 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tanabe Seiyaku
  • Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Irritable bowel syndrome therapies
  • Mechanism of Action Alpha4-beta7 integrin antagonists; Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Irritable bowel syndrome; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 24 Jan 2007 Removed [synonyms] from overview, which were already present in the synonyms list.
  • 25 Feb 2003 Discontinued - Phase-I for Irritable bowel syndrome in Europe (PO)
  • 25 Feb 2003 Discontinued - Phase-I for Irritable bowel syndrome in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top